Core Viewpoint - China Resources Double Crane (华润双鹤) has received the drug registration certificate for Compound Amino Acid Injection (18AA-Ⅸ) from the National Medical Products Administration, indicating a significant step in the company's product development and market entry strategy [1] Group 1: Product Development - The company initiated the research and development of the Compound Amino Acid Injection (18AA-Ⅸ) in October 2022 and submitted the application for market approval on October 20, 2023, which was accepted on October 27, 2023 [1] - The expected approval date for the product is June 24, 2025, highlighting the timeline for market entry [1] - The total R&D investment for this product has reached 10.7435 million yuan [1] Group 2: Market Potential - The global sales figure for "Neoamiyu" in 2023 is reported to be 32.2056 million USD, indicating a substantial market presence [1] - In the domestic market, the total sales for Compound Amino Acid Injection (18AA-Ⅸ) are projected to be 120 million yuan in 2024, with Guangzhou Green Cross Pharmaceutical Co., Ltd. holding a 100% market share [1]